Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

Examining the Economic Impacts of Biosimilars in Oncology

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    Not only can biosimilars impact the health of our patients with cancer, but they can also contribute to cost savings for the healthcare system as a whole. Here to dive further into the economic impacts of biosimilars in the oncology space with Dr. Mary Katherine Cheeley is Dr. Sophia Humphreys, Director of System Pharmacy Formulary Management and Clinical Programs at Sutter Health.

Recommended
Details
Presenters
Comments
  • Overview

    Not only can biosimilars impact the health of our patients with cancer, but they can also contribute to cost savings for the healthcare system as a whole. Here to dive further into the economic impacts of biosimilars in the oncology space with Dr. Mary Katherine Cheeley is Dr. Sophia Humphreys, Director of System Pharmacy Formulary Management and Clinical Programs at Sutter Health.

Schedule6 Oct 2024